ArticleJournal of critical care2020
The chimeric antigen receptor-intensive care unit (CAR-ICU) initiative: Surveying intensive care unit practices in the management of CAR T-cell associated toxicities.
Article in Journal of critical care, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 53 citations in OpenAlex.
- Utilization patterns of hematology consultation in the intensive care unit: an 11-year single-center experience.Blood advances · 2026Article
- Economic evaluation of critically ill adult CAR-T cell recipients-analysis from a healthcare payer perspective.Medizinische Klinik, Intensivmedizin und Notfallmedizin · 2025Article
- CAR-T therapy: Advances in respiratory diseases.Chinese medical journal pulmonary and critical care medicine · 2025Review
- Biology-driven therapies of CAR T immune effector cell-associated neurotoxicity syndrome.Immunotherapy · 2025Review
- Evolving strategies for addressing CAR T-cell toxicities.Cancer metastasis reviews · 2024Review
- Updates on Chimeric Antigen Receptor T-Cells in Large B-Cell Lymphoma.Biomedicines · 2024Review
- Decoding the Nexus: Cellular and Molecular Mechanisms Linking Stroke and Neurotoxic Microenvironments in Brain Cancer Patients.Biomolecules · 2024Review
- Intensive care unit admission criteria: a scoping review.Journal of the Intensive Care Society · 2024Article
- Riding the storm: managing cytokine-related toxicities in CAR-T cell therapy.Seminars in immunopathology · 2024Review
- Chimeric Antigen Receptor T-Cell Postinfusion Fever: Infection Profile, Clinical Parameters, and Biomarkers Trends to Assist Antibiotic Stewardship.Open forum infectious diseases · 2024Article
- Current understanding and management of CAR T cell-associated toxicities.Nature reviews. Clinical oncology · 2024Review
- Self-regulating CAR-T cells modulate cytokine release syndrome in adoptive T-cell therapy.The Journal of experimental medicine · 2024Article
- Toxicities, intensive care management, and outcome of chimeric antigen receptor T cells in adults: an update.Critical care (London, England) · 2024Review
- Patterns of neurotoxicity among patients receiving chimeric antigen receptor T-cell therapy: A single-centre cohort study.European journal of neurology · 2024Article
- [With a tumor diagnosis in the intensive care unit].Innere Medizin (Heidelberg, Germany) · 2023Review
- Article
- Cytokine Release Syndrome and Sepsis: Analogous Clinical Syndromes with Distinct Causes and Challenges in Management.Infectious disease clinics of North America · 2022Review
- Interleukin Inhibitors in Cytokine Release Syndrome and Neurotoxicity Secondary to CAR-T Therapy.Diseases (Basel, Switzerland) · 2022Review
- Infectious Complications in Pediatric, Adolescent and Young Adult Patients Undergoing CD19-CAR T Cell Therapy.Frontiers in oncology · 2022Article
- Chimeric Antigen Receptor-Engineered Natural Killer (CAR NK) Cells in Cancer Treatment; Recent Advances and Future Prospects.Stem cell reviews and reports · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
27 authors at 17 institutions in 1 country.
Funding
Abstract
purposeA task force of experts from 11 United States (US) centers, sought to describe practices for managing chimeric antigen receptor (CAR) T-cell toxicity in the intensive care unit (ICU). MATERIALS AND
methodsBetween June-July 2019, a survey was electronically distributed to 11 centers. The survey addressed: CAR products, toxicities, targeted treatments, management practices and interventions in the ICU.
resultsMost centers (82%) had experience with commercial and non-FDA approved CAR products. Criteria for ICU admission varied between centers for patients with Cytokine Release Syndrome (CRS) but were similar for Immune Effector Cell Associated Neurotoxicity Syndrome (ICANS). Practices for vasopressor support, neurotoxicity and electroencephalogram monitoring, use of prophylactic anti-epileptic drugs and tocilizumab were comparable. In contrast, fluid resuscitation, respiratory support, methods of surveillance and management of cerebral edema, use of corticosteroid and other anti-cytokine therapies varied between centers.
conclusionsThis survey identified areas of investigation that could improve outcomes in CAR T-cell recipients such as fluid and vasopressor selection in CRS, management of respiratory failure, and less common complications such as hemophagocytic lymphohistiocytosis, infections and stroke. The variability in specific treatments for CAR T-cell toxicities, needs to be considered when designing future outcome studies of critically ill CAR T-cell patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.